Freedom of Information Request	FOI 21-419	21st October 2021

Q1. How many patients were treated in August 2021 (or latest available month) by the gastroenterology department with the following drugs:

Please find below data provided for August 2021 for gastroenterology only across the Health Board. Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

- **Adalimumab (any brand or biosimilar)**

Type	Quantity
ADALIMUMAB (AMGEVITA) 40 mg in 0.8mL Pre-Filled Pen 2 Pre-Filled Pen Pack	269
ADALIMUMAB (AMGEVITA) 40 mg in 0.8mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	4
ADALIMUMAB (HUMIRA) 40 mg in 0.4mL Pre-Filled Pen 2 Pre-Filled Pen Pack	4

- **Infliximab (any brand or biosimilar)**

Type	Quantity
INFLIXIMAB (INFLECTRA) 100 mg Intravenous Infusion 1 Vial Pack	490

- **Ustekinumab (Stelara)**

Type	Quantity
USTEKINUMAB 130 mg in 26mL Intravenous Infusion 1 Vial Pack	3
USTEKINUMAB 90 mg in 1mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	43

- **Vedolizumab (Entyvio)**

Type	Quantity
VEDOLIZUMAB 108 mg in 0.68mL Pre-Filled Pen 1 Pre-Filled Pen Pack	210
VEDOLIZUMAB 300 mg Intravenous Infusion 1 Vial LP Pack	15
VEDOLIZUMAB 300 mg Intravenous Infusion 1 Vial Pack	65

- **Tofacitinib (Xeljanz)**
- **Filgotinib (Jyseleca)**

Q2. How many patients were treated in August 2021 (or latest available month) for Crohn's Disease ONLY with the following drugs:

- **Adalimumab (any brand or biosimilar)**
- **Infliximab (any brand or biosimilar)**
- **Ustekinumab (Stelara)**
- **Vedolizumab (Entyvio)**

The Health Board does not record this information centrally. In order to determine this, the Health Board would have to review every patient record. Therefore, in order to comply with your request the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000, which is currently £450. As you will be aware, this is not an exemption, which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.